[HTML][HTML] Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies
N Mylonas, PE Nikolaou, P Karakasis… - International Journal of …, 2024 - mdpi.com
Endothelial dysfunction often precedes the development of cardiovascular diseases,
including heart failure. The cardioprotective benefits of sodium-glucose cotransporter 2 …
including heart failure. The cardioprotective benefits of sodium-glucose cotransporter 2 …
Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction
Background Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-
cause mortality when started within 14 days of acute myocardial infarction (AMI). Objectives …
cause mortality when started within 14 days of acute myocardial infarction (AMI). Objectives …
[HTML][HTML] Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
J Carberry, G Marquis-Gravel, E O'Meara… - JACC: Heart Failure, 2024 - Elsevier
As a result of the widespread use of reperfusion therapies and secondary prevention over
the last 30 years, there has been a dramatic reduction in the risk of mortality and …
the last 30 years, there has been a dramatic reduction in the risk of mortality and …
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design
Aims Patients with a reduced left ventricular ejection fraction (LVEF) following an acute
myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can …
myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can …
News in cardiovascular pharmacotherapy from the ACC. 24 Meeting
Several interesting advances in cardiovascular pharmacotherapy were presented at the
American College of Cardiology Annual Scientific Session (ACC. 24) recently in Atlanta. The …
American College of Cardiology Annual Scientific Session (ACC. 24) recently in Atlanta. The …
2024ACC 热点速递： REDUCE-AMI 和EMPACT-MI 临床研究解读
龙琦， 廖梦阳， 廖玉华， 袁璟 - 临床心血管病杂志, 2024 - lcxxg.whuhzzs.com
2024ACC热点速递:REDUCE-AMI和EMPACT-MI临床研究解读 杂志社主页 期刊 1.{{journal.titleCn}}
{{journal.titleCn}} {{journal.titleCn}} {{journal.titleCn}} {{subColumn.name}} 2.{{journal.titleCn}} …
{{journal.titleCn}} {{journal.titleCn}} {{journal.titleCn}} {{subColumn.name}} 2.{{journal.titleCn}} …
Weekly Journal Scan: sodium/glucose cotransporter 2 inhibition after myocardial infarction still in the grey area
G Liuzzo, C Patrono - 2024 - academic.oup.com
• The EMPACT-MI trial (Study to Evaluate the Effect of Empagliflozin on Hospitalization for
Heart Failure and Mortality in Patients with Acute Myocardial Infarction) was a company …
Heart Failure and Mortality in Patients with Acute Myocardial Infarction) was a company …
Empagliflozin: primum inter pares among sodium-glucose cotransporter-2 inhibitors?
Abstract Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic
medications which have proved capable of providing breakthrough cardiovascular benefits …
medications which have proved capable of providing breakthrough cardiovascular benefits …
Highlights from 2024 ACC: Clinical study interpretation of REDUCE-AMI and EMPACT-MI
L Qi, L Mengyang, L Yuhua, Y Jing - J Clin Cardiol, 2024 - en.whuhzzs.com
Abstract In the 2024 American College of Cardiology (ACC) scientific sessions, the results of
the REDUCE-AMI and EMPACT-MI studies showed that β-blocker and SGLT2i have not …
the REDUCE-AMI and EMPACT-MI studies showed that β-blocker and SGLT2i have not …
[HTML][HTML] Estudio EMPACT-MI: Empagliflozina después de un Infarto Agudo al Miocardio
FA Florit - sochicar.cl
La disfunción sistólica post infarto al miocardio es un importante factor de riesgo que se
relaciona al desarrollo de insuficiencia cardiaca (IC) a largo plazo, ya su vez, el desarrollo …
relaciona al desarrollo de insuficiencia cardiaca (IC) a largo plazo, ya su vez, el desarrollo …